Review Article
Volume 12:3, 2023

International Journal of Economics & Management Sciences

ISSN: 2162-6359 Open Access

Is It Right to Claim COVID-19 Vaccine Liabilities In Accordance with Indian Law of Tort from the Present Economic Conditions of Pandemic?

Ayush Das*

Department of Economics and Management Sciences, SVKM's NMIMS, Mumbai, Maharashtra, India

Abstract

The deterrent component of tort law is highlighted by the economic theory of tort law. It is predicated on the notion that responsibility for unintentional injury should be allocated. in order to reduce the predicted costs of accidents, such as those incurred by the victims, the expense of taking safeguards to prevent injuries and victims, and the administrative costs of determining fault. This research tries to examine tort liability from an economic perspective. This work does not consider each and every tort law idea, but rather focuses on a few that are more closely related to tort law than others and all of them work together harmoniously to produce a seamless body of study, which is the goal of this work.

It investigates the possible significance of risk-benefit analysis in determining the appropriateness of the COVID-19 vaccination. It is argued that a comprehensive flexible approach to determining defectiveness that embraces risk-benefit can take into account the enormous public interest derived from the continued supply and availability of vaccines, as well as the benefits of immunity for both the individual and the community. The immunity-granting advantages of the COVID-19 vaccinations for both the individual and the community should be significant in any assessment of defectiveness if situations involving the liability of the vaccine do arise. Such a comprehensive, adaptable approach to defects that considers risk and benefit can be used to assess a vaccine's safety and potentially lessen its risks decreasing public trust in the vaccine update.

Keywords: Immunity-granting • Central Drug Control Organization (CDCO) • Drug Controller General of India (DGCI) • Covesheild • Culpable Homicide

Introduction

Under the national criminal tort consumer law, lawsuits can be filed against medical malpractice. A significant step in slowing the spread of the pandemic and further lowering the disease and fatalities it causes is the release of the COVID-19 vaccine. The launch of the COVID-19 vaccine is the greatest drive in history, and its rollout necessitates planning on many different levels.

India was the country where the Oxford-Astra Zeneca vaccine, which serum institute of India produces under licence under the brand name Covesheild, and Covaxin, a locally developed vaccine by Bharat Biotech, received their initial approvals.

They have been joined by the Sputnik V (produced under licence by Dr. Reddy's laboratories), along with the Serum institute of India, which started operations in September, Moderna vaccines, Johnson and Johnson vaccine, and other vaccine candidates undergoing regional clinical trials.

According to a June 2022 study that was published in the Lancet, the COVID-19 vaccination prevented an additional 4.2 million fatalities in India between December 8 of 2020 and December 8 of 2021. In the 20th and 21st centuries, vaccines have been crucial in improving medical care. However, no medical procedure is risk-free, and vaccinations are no exception. Generally speaking, India has approved four COVID-19 vaccines: Covishield Covaxin Sputnik V Moderna's vaccine for emergency use, although there is still uncertainty regarding compensation for any adverse events (side effects or medical issues) resulting from immunization. India just began one of the largest immunisation campaigns, with the goal of eventually vaccinating every resident. Each time a human epidemic has struck, vaccine liability has come up. So, this inquiry is quite pertinent use, an individual can still pursue legal action to obtain compensation [1,2].

***Address for Correspondence:** Ayush Das, Department of Economics and Management Sciences, SVKM's NMIMS, Mumbai, Maharashtra, India, Tel: 9073579901; E-mail: ayushdasayushda8@gmail.com*

Received: 21 January, 2023, Manuscript No. IJEMS-23-87650; **Editor assigned:** 24 January, 2023, PreQC No. IJEMS-23-87650 (PQ); **Reviewed:** 08 February, 2023, QC No. IJEMS-23-87650; **Revised:** 28 April, 2023, Manuscript No. IJEMS-23-87650 (R); **Published:** 08 May, 2023, DOI: 10.37421/2162-6359.2023.12.687

Question of the research topic

Is it right to claim COVID-19 vaccine liability in accordance with Indian law of tort from the present economic condition of pandemic?

Benefits: Although the government of India has organised an inoculations drive for emergency use, both the vaccine manufacturer and the approving authority are liable to pay compensation to the injured party or his or her next of kin if a tort case of accident arising out of composite negligence can be established by the plaintiff in a court of law for fault liability. The manufacturer of COVID-19 vaccine, whether a patent-holder or a licensee, is liable to pay compensation even if the plaintiff can prove that the manufacturer was the payment of compensation, regardless of the challenge parties' fault, may be sanctioned by the stringent liability rule U, the adoption of a new statute, or an issue directive.

Compensation from the approving authority under drugs and cosmetics act 1940

The approving authority: Under the drugs and cosmetics act of 1940, the Drug Controller General of India (DGCI), the Central Drug Control Organization (CDCO), and either or both of the Central and State governments acting as administering or distributing agents of the manufacturer vaccine are also liable to pay compensation for contributory negligible damages.

Claim under total accidents act 1855: According to the total accident act of 1955, if there are unfavourable side effects from a vaccination produced or administered by any agency that cause the vaccinated to suffer loss or injury, including permanent disability or death, the vaccinated may bring a legal action against the injured party's representative in a court of law to seek compensation for losses resulting from:

- Medical expenses incurred to treat the injury from the adverse side effects of the vaccine.
- Impaired earning capacity of the vaccinated party as a result of the injured caused by the adverse side effects of the vaccine. Disablement The vaccinated party suffers harm or loss as opposed to some sort of pre-exiting event.
- The pain and suffering of the vaccinated party who suffers harm or the pain and suffering of his or her next of kin in the event of death due to the vaccine's unfavourable side effects are intrinsically intangible elements that are in breach of the duty of care that all challenged parties owe to the vaccinated party and are a direct cause of the death. Disablement injury or loss to the vaccinated party and not any pre-exiting condition that appeared as their death or disability without the administering party's knowledge.

Criminal law

- Filing a FIR under section 304 A of the Indian penal code 1860, as well as sections 34, which causes: Death by roch or negligent act not amounting to culpable homicide, with a common intention for police investigation using forensic evidence of the product in question, medical-legal certificates given to the injured if alive, or post mortem examination of the deceased patient.

- Submitting a FIR under sections 336, 337, and 338 of the Indian penal code 1860 for causing: Death by hasty or negligent act not amounting to culpable homicide for doctors and medical staff so that police can investigate the case using forensic evidence of the way the patient was treated and administered their medication.

Claim under consumer protection act: Filing of a civil lawsuit under the consumer protection act of 2019 seeking compensatory damages for product liability cases with consumer dispute resolution organisations at the district, state, and federal levels.

Why do I choose the topic: Inadequate policies to address the root causes of inequality that most affect those living in conditions of vulnerability to access needed health and social services have made the problem worse. The COVID-19 pandemic has resulted in a terrible loss of life, disproportionately affecting the poor and those with underlying health conditions. Additionally, this pandemic has demonstrated the shaky interdependence of health and the economy during a disease outbreak. With COVID-19 exposing structural flaws and inequities in access to health, the impact on the economy and sustainable development is obvious. The health and well-being of people depend on inclusive, sustainable economic and social development policies that benefit everyone in society. A healthy economy cannot exist without healthy people. There is a growing consensus regarding the necessity of taking a critical look at the future in terms of health social and economic policies as we become aware that this health crisis may persist over time. So that people and communities can be protected and survive in the face of complex challenges and risks, whether they be biological, ecological, or economic in origin, fundamental adjustments are needed in the way we approach health and economic society. Health governance and the capability of health systems to respond at the national and local levels in a coordinated manner are key components of the ability to respond to a pandemic internationally. Health systems that are fragmented, segmented, poorly coordinated, and financially strapped and do not adequately serve their populace's needs under normal conditions will not be able to address those demands in the event of large public health catastrophes. Hope is offered in the recent rapid development of COVID-19 vaccinations. The worst pandemic to occur in a century. However, access to vaccinations is extremely challenging in many countries, in part due of tight intellectual property laws. These regulations make it more difficult for countries to achieve full economic and social [3,4].

Realising the right of their people to health commodification of important medications, including vaccinations, forces developing nations into excessive debt and perpetuates national disparities that target vulnerable populations. Programs for vaccines are an investment in a nation's human capital. They increase public health life expectancy and productivity because emerging diseases may spread more slowly in the absence of a vaccine. The goal of selecting this research topic was to demonstrate the relationship between the demand for vaccinations and better Indian economic development policies.

Literature Review

Numerous people in India, which has the second-largest population in the world, have the COVID-19 disease. Coronavirus instances first appeared in India as a result of international connections rather than domestic spread. Because of the restricted transmission throughout a lockdown and social seclusion yet at the end of all lockdown stages, it was thought that India was handling the

legal number of positive cases from COVID-19 well. 1,90,648 confirmed cases, including 5407 from this disease, were reported in India. Clinical signs of COVID-19 include fever (not always), breathing problems, coughing, lethargy, headaches, sore throats, and other symptoms. It is therefore extremely difficult to identify this illness from other respiratory illnesses. The Indian government (at both the national and state levels) is making a concerted effort to reduce the number of cases and related effects on a daily basis and is taking every necessary action to address the problems and threats posed by this escalating invisible pandemic battle. In India, more than 80% of people support receiving anti-COVID vaccinations. India has one of the lowest vaccination rates worldwide. In the first month of 2021, there was vaccine reluctance, especially among poor and tribal groups and in rural India. Government and public awareness campaigns continuously reduce vaccine reluctance significantly. Since May 2021, rural areas in India account for more than half of the daily doses given. Vaccination facilities in India have seen. COVID vaccination is quite popular, which leads to overcrowding and poor management. As a result of the enormous number of people who showed up for immunization in April and May, many centres across India reported a significant scarcity of the COVID vaccine. Due to the shortfall, many people in cities like Mumbai, New Delhi, and Bengaluru who had waited for hours to obtain their COVID vaccine did not receive it. Since July, the supply of vaccines has dramatically increased, and India has begun immunizing children [5].

According to a research on vaccine acceptability, 79.5% of Delhi residents wish to receive the COVID-19 vaccine. Another published study from West Banal, an eastern Indian state, found that 77.27% of respondents wish to receive the COVID-19 vaccine. Over 75% of people wish to receive the COVID-19 vaccination, it may be assumed based on the results of these two tests.

The COVID-19 vaccine, like many other vaccinations, carries a risk of negative side effects. The most frequent adverse reactions, according to India's union ministry of health and family welfare, include headaches, fever, agitation, and soreness and swelling near the injection site.

The Oxford vaccine, also known as Covisheild, is known to cause joint pain, nausea, and exhaustion, according to the UK Government. Medical professionals in India maintain that vaccination use is safe and that the advantages outweigh the risks. It has a loose connection to vaccinations.

617 severe adverse events in all were reported. On March 29 of these 180 cases, which resulted in deaths, the ministry analysed 192000 case reports, including 12400 deaths, and determined that acute coronary syndrome was the cause of death. However, only 3500 cases' documentation was comprehensive.

By the seventh of June, 26000 adverse events had been reported as a result of vaccination; of these, 24901 were minor, 412 were significant, and 887 were serious; 488 deaths, including 301 men and 178 women, had also been reported (details of 9 about 0.01% and a fatality rate of about 0.0001%-24703 events and 457 deaths from 210 million Covishield doses). Following 25 million doses of Covaxin, there were 1497 incidents and one fatality [6].

The state with the most unfavourable events reported was Maharashtra (4521), then Kerala (4074), Karnataka (2650), and West Bengal (1456).

Out of roughly 60 million doses administered during that time period, the authorities published a study of case reports on June 15 that focused on 31 cases and one death from anaphylaxis that were widely believed to have been caused by the vaccination. The majority of these occurrences were categorised as coincidental undetermined or unclassified, with the exception of three cases and one patient death (68 years old) that were determined to be "vaccine product related." The vaccinations were to blame for the incidents. Only a thorough investigation and casualty evaluation will be able to reveal whether there was a coincidental connection between the incident and the vaccine.

Articles: Solving the COVID-19 vaccine product liability problem S Halabi CSAS working paper 21-11, 2020.

The COVID-19 vaccination roll-out has begun globally. In order to distribute vaccinations to patients around the world, governments have committed billions of dollars in funding research, development, logistic and supply chains, as well as networks of healthcare providers. The COVAX facility was established by the European commission and a number of international organisations to combine funding for deserving candidates and support the purchase of those candidates by low and middle-income nations. However, making an upfront investment in vaccine development and distribution only addresses half of the issue of vaccine access. How vaccine producers participate will depend in large part, if not entirely, on risks to legal obligations, notably product responsibility for serious side effects [7].

We used recently licenced and authorized COVID-19 vaccinations in the emergency response. They won't ship vaccines if they don't get enough protection from legal risk, particularly product liability. Phase 111 trials and the early administration of EUA vaccines provide compelling evidence that serious adverse effects following immunisation are unavoidable despite the limited expertise with creating coronavirus vaccines. In order to help the community develop strong immunity, it is crucial to strike a balance between the risk assessments of manufacturers and the justice for vaccine recipients who suffer significant illness or pass away.

Global vaccination campaigns are already under progress, thanks in large part to the terrible effects of the COVIV 19 global pandemic, which has accelerated the development of vaccinations against the SARS-CoV-2 virus. Resuming social engagement, employment, and travel will be made easier with the introduction of widespread or even required vaccination, but this step is not without risks. Receivers of vaccinations are subject to important queries regarding responsibility and payment for vaccination related harm. Two COVID-19 vaccines have already been linked to rare blood clotting reactions, some of which have been fatal. Traditional methods of obtaining compensation, like as liability based litigation, product liability systems, and leaving legislative scheme, may not be sufficient for people who suffer harm from vaccines. Despite the fact that several nations have established vaccine injury compensation programmes, many European nations and Australia have been reluctant to create a no fault system to address potential vaccination related injuries. This article evaluates whether current compensation systems, such as liability based tort claims functioning under common law and civil jurisdiction, adequately address vaccine related injury. The development of a no-fault system to address the possibility of vaccination related injuries has been resisted by several European nations and

Australia, despite the introduction of vaccine injury compensation plans in a substantial number of nations worldwide. This article examines whether existing compensation mechanisms, such as liability based claims operating in common law and civil regimes, are sufficient avenues for injured parties to seek compensation. Europe and Australia. Are compared because they now take a liability-exemption approach rather than a no fault approach to vaccine harm compensation, which bears striking similarities [8].

92 low and middle-income nations offer vaccination harm compensation programmes. In contrast to liability based causes of action, the authors suggest that the implementation of a no-fault vaccine injury compensation programme is a desirable mechanism to recompense vaccination easily means of accessing compensation. No-fault vaccination injury compensation programmes ought to be a top priority on lawmakers' reform agendas as vaccination campaigns get underway (Figure 1).

Age Group	Vaccination
12-14	6,69,91,865
15-17	11,22,70,707
18-44	1,11,84,08,131
45-60	41,68,69,985
60+	28,41,64,908

Figure 1. Vaccine administration by age group, vaccinations in India by age group as of August 1, 2022.

Data and methodology

Asian development bank org: The national debt of India: Prior to the outbreak of the Coronavirus disease, India's national debt was rated as being high but manageable. According to a report released by the international monetary fund in December 2019, the debt component was sustainable due to favourable debt dynamics and financial repression, as the statutory liquidity requirement had created a domestic captive market for debt that constrained the interest cost of debt. The fact that governmental debt is primarily held in home currency by citizens has further reduced risks. Real GDP (Gross Domestic Product) growth shocks and fiscal slippages were the key threats to debt sustainability.

The Asian development outlook supplement 2021 predicts growth of 10.0% in the fiscal year 2023, despite The Reserve Bank of India anticipates a 9.5% GDP increase.

World Health Organizations (WHO): On February 17, 2021, the WHO and Chuble limited, through ESISS INC, a Chuble company, signed an agreement for the administration of a no fault and only vaccine injury compensation mechanism operating on a global scale. The programme will provide eligible individuals in AMC-eligible countries with a quick, fair, robust, and transparent process to receive compensation for uncommon but serious adverse events associated with COVAX distribution.

The COVAX programme seeks to greatly decrease the need for recourse to the legal system, a potentially drawn-out and expensive procedure, by offering a no-fault lump sum payment in full and final settlement of any claim. As with all pharmaceuticals, even those that have been approved for use by the general population, including vaccinations.

India started vaccination programme from January 16 2021 the progress of India's vaccination.

As of April 27, 2022, 62.2% of the overall population participated in the programme. In response to the recent increase in new variant-led cases worldwide, India has stepped up its vaccination campaign by implementing precaution doses and vaccination for the 12–14 age group. The Current Situation Index (CSI) from the consumer confidence survey of the reserve bank indicates a sharp fall from 85.6 in March 2020 to 63.7 in May 2020, dropping further to second wave. However, the second wave's progressive abatement suggests skepticism regarding the state of the economy today. The Future Expectation Index (FEI) remained at a high level throughout the majority of the intensity of limitation during the corresponding pandemic waves (Figure 2).



Figure 2. August 2022 review of Indian economy: Macro-economic performance.

Results

The COVID-19 vaccine producer is not protected in India from any issues or negative effects resulting from the use of their labs.

Both Serum Institute of India and Bharat Biotech, the makers of Covishield and Covaxin, are required to notify the authorities of any health complications resulting from the use of vaccines.

The negative consequences of vaccines involve vaccine producing corporations in court battles, which frequently result in the imposition of significant fines and compensation. In order to protect themselves from potential future legal action or liabilities resulting from their adverse effects, these vaccine producing corporations are asking the government of India for indemnity protection.

The serum institute of India was asked to pay five crore rupees in compensation last year due to severe adverse effects from vaccine studies. Since then, the serum institute of India has emphasised the necessity of providing vaccine makers with indemnity protection.

The vaccine and the Indian government currently have a contract in place.

Manufacturing companies include a liability clause that holds vaccine producers entirely responsible for any harm caused by the vaccination. According to the serum institute of India, the Indian government will implement legislation to shield vaccine producers from legal actions. "Vaccine manufacturers should not be held liable for inevitable safety risks in vaccines or safety hazards in a safety are long as the vaccine was properly manufactured and accompanied by sufficient warning," the second restatement of torts stated. Additionally, the Indian Constitution's Article 294(4) permits government liability to result from contracts. Additionally, the government may be held vicariously accountable for the actions of vaccine producers.

Therefore, by virtue of the government of India becoming responsible for vaccine manufacturing, accordance with the inclusion of an indemnification provision (Figure 3).



Brand	Vaccination
Covishield	1,62,85,41,198
Covaxin	34,13,79,237
Sputnik V	12,32,171
Corbevax	6,69,78,452
Covovax	21,533

Figure 3. Vaccine administration by vaccine brand, vaccination in India by brand as august 1, 2022.

Discussion

In the first day or two after receiving the COVID-19 vaccination, it is very usual to have the following adverse effects:

- Discomfort and a heavy, unpleasant feeling where the injection was given.
- Having chills, a headache, and fatigue.
- Nausea, vomiting, and diarrhea.
- Minor influenza-like symptoms.

These typical side effects are far less dangerous than getting a Coronavirus or a Coronavirus related problem. They typically disappear within a few days. We can take a nap and take paracetamol as recommended on the label or leaflet if we are uncomfortable.

A safe and effective COVID-19 vaccination is currently the subject of intense interest on a global scale. Receivers of vaccinations are exposed to the possibility of rare but substantial side effects, raising important questions about responsibility and compensation for vaccination related injury. Rare blood has already been present two COVID-19 vaccines have already been linked to a rare blood clotting reaction, the same of which was fatal.

Traditional methods of accessing compensation, such as liability based litigation, product liability regimes, and extinguishing statutory schemes, may be insufficient avenues of getting compensation for those who suffer vaccine related harm. Numerous European nations and Australia have been reluctant to adopt a no-fault system to address potential vaccination-related injuries, despite a sizable number of nations introducing compensation plans for vaccine injuries. This article evaluates whether current compensation systems, such as liability based tort claims operating in common law and civil regimes, are acceptable ways for harmed people to get compensation. The COVAX vaccine injury compensation programme is accessible in 92 developing and middle-income nations. Compared to liability based causes of action, I come to the conclusion that the implementation of a no-fault vaccine injury compensation scheme is a desirable mechanism to compensate vaccination-related injuries by providing a more effective and convenient manner of accessing compensation. Legislators' reform agenda should place the urgent introduction of no-fault vaccine injury compensation plans at the top of the list.

It would be possible to establish a complete system for no-fault vaccine injury compensation, which would advance justice. Excluding nations unable to provide millions of people with the vaccine's promised protection. Allowing access to COVID-19 vaccines without ensuring that people who have serious adverse events will be compensated would benefit uninjured people at the expensive of injured people. Compared to liability based causes of action, I come to the conclusion that the implementation of a no-fault vaccine injury compensation scheme is a desirable mechanism to compensate vaccination-related injuries by providing a more effective and convenient manner of accessing compensation. Legislators' reform agenda should place the urgent introduction of no-fault vaccine injury 13 compensation plans at the top of the list. It would be possible to establish a complete system for no-fault vaccine injury compensation, which would advance justice. Excluding nations unable to provide

millions of people with the vaccine's promised protection provide a model for upcoming immunisation programmes (Figure 4).

Gender	Vaccination
Male	99,31,56,086
Female	95,53,01,813
Others	4,73,074

Figure 4. Vaccine administration by gender, vaccinations in India by gender as of August 1, 2022.

Conclusion

According to the findings of the literature review, the COVID-19 immunisation is more successful in India than it is in many other nations. Although a sizable portion of Indians have received vaccinations, the timing of the first outbreak remains undetermined. If a new variation reappears, a second dose and booster will be effective. However, the immunisation drive's success in India cannot be disputed. A substantial sum of money has been paid to execute the immunisation programme because India has the second-largest population in the world. Indian economy has had a setback as a result of three waves of COVID (first, second, and even third). Other than restricting labour migration and providing oxygen and medicine (hydroxychloroquine), India has offered assistance and extended its hands. Of cooperation to its neighboring countries like every other nation, India's economy experienced a downturn in comparison to its neighbours. However, looking ahead at the current situation, economists are optimistic that the Indian GDP will recoup its lost vigour in the ensuing fiscal years.

My research paper focuses on “economic theory of tort in respect to COVID-19 vaccination” so this case it is my as responsible Indian citizen to have some commitment towards my nation. COVID-19 vaccination needs some research. Those dark days of COVID weather social economic or health is unlikely to be forgotten but whatever hurdle is there in the way we can help central as well as state government to overcome them. Though the fourth wave of COVID hasn’t posed a threat of our economy but there is no change in the mortality rate. Keeping in mind about the future security it is important to have research continuation. Not only the research needs a large amount of money but also we needs a large a proper communication with those countries that are keen on this. Although India is successful in COVID-19 vaccination but keeping in mind about the future we need various projects, research infrastructure, awareness programmea appropriate dialogue with those nations interested in this Despite India's achievement in COVID-19 immunisation, we still need a variety of projects, research infrastructure, and awareness programmes to prepare for the future. When considering the future, multiple projects, research infrastructure, and awareness campaigns are required.

India's vast population is one of the primary causes of its severe COVID outbreak. It is not simple to inoculate such a large group and bring them under one roof. Because these vaccines were distributed quickly on the market, it was seen that several side effects of these vaccines were experienced by a large number of people. No, not everyone in the community was afflicted. Some people only had minor symptoms and recovered in two days. Therefore, it is incorrect to claim that people suffer negative effects and that cases of death do occur. The tort law is mentioned in our Indian constitution, and we might offer compensation on its 15 basis. I believe there is no need to request compensation from the government if the health conditions are not too bad. India is the second most populous nation in the world, and even if compensation were to be given to just 5% of the people there, 75 lakh individuals would do so, which would be troublesome for India at the moment given its economic predicament. A stable economy is necessary for putting emphasis on vaccination reachers and other issues because we do not know the future of COVID. In my opinion, vaccination businesses and the government should offer compensation to those who experienced losses as a result of COVID. Those with little influence must assist only if the government acts independently rather than requesting assistance can we soon anticipate a COVID-free world and a stable economy.

References

1. Callaway, Ewen. "Coronavirus vaccines." *Nature* 580 (2020): 577.
2. Callaway, Ewen. "COVID vaccine boosters: The most important questions." *Nature* 596 (2021): 178-180.
3. Saif, LJ. "Animal coronavirus vaccines: Lessons for SARS." *Dev Biol* 119 (2004): 129-140.
4. GAO, Wentao, Azaibi Tamin, Adam Soloff, and Leonardo D'Aiuto, et al. "Effects of a SARS-associated coronavirus vaccine in monkeys." *Lancet* 362 (2003): 1895-1896.
5. Harris, Phil, and Danny Moss. "Managing through the COVID second wave: Public affairs and the challenge of COVID vaccination." *J Public Aff* 21 (2021): 2642.
6. Nemoto, Manabu, Toru Kanno, Hiroshi Bannai, and Koji Tsujimura, et al. "Antibody response to equine coronavirus in horses inoculated with a bovine coronavirus vaccine." *J Vet Med Sci* 79 (2017): 1889-1891.
7. Yong, Chean Yeah, Hui Kian Ong, Swee Keong Yeap, and Kok Lian Ho, et al. "Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus." *Front Microbiol* 10 (2019): 1781.
8. Saif, LJ. Coronavirus immunogens. Vet Microbiol 37 (1993): 285-297.

How to cite this article: Das, Ayush. "Is It Right to Claim COVID-19 Vaccine Liabilities In Accordance with Indian Law of Tort from he Present Economic Conditions of Pandemic?." Int J Econ Manag Sci 12 (2023): 687.